{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T04:01:18Z","timestamp":1784865678353,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"DOI":"10.1007\/s00210-026-05751-6","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T03:09:24Z","timestamp":1784862564000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Drug-specific timing and fatality patterns of EGFR-TKI-associated interstitial lung disease in NSCLC-related JADER reports"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9543-9053","authenticated-orcid":false,"given":"Burak","family":"Pacaci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1901-5603","authenticated-orcid":false,"given":"Osman","family":"Kostek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"issue":"16","key":"5751_CR1","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1200\/JCO.2005.04.9866","volume":"24","author":"M Ando","year":"2006","unstructured":"Ando M, Okamoto I, Yamamoto N et al (2006) Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 24(16):2549\u20132556. https:\/\/doi.org\/10.1200\/JCO.2005.04.9866","journal-title":"J Clin Oncol"},{"issue":"4","key":"5751_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0154425","volume":"11","author":"M Fujiwara","year":"2016","unstructured":"Fujiwara M, Kawasaki Y, Yamada H (2016) A pharmacovigilance approach for post-marketing in Japan using the Japanese Adverse Drug Event Report (JADER) database and association analysis. PLoS ONE 11(4):e0154425. https:\/\/doi.org\/10.1371\/journal.pone.0154425","journal-title":"PLoS ONE"},{"issue":"12","key":"5751_CR3","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1016\/j.jtho.2020.08.025","volume":"15","author":"A Gemma","year":"2020","unstructured":"Gemma A, Kusumoto M, Sakai F et al (2020) Real-world evaluation of factors for interstitial lung disease incidence and radiologic characteristics in patients with EGFR T790M-positive NSCLC treated with osimertinib in Japan. J Thorac Oncol 15(12):1893\u20131906. https:\/\/doi.org\/10.1016\/j.jtho.2020.08.025","journal-title":"J Thorac Oncol"},{"key":"5751_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ejca.2022.10.029","volume":"179","author":"M Imaji","year":"2023","unstructured":"Imaji M, Fujimoto D, Sato Y et al (2023) Safety and efficacy of osimertinib rechallenge or continuation after pneumonitis: a multicentre retrospective cohort study. Eur J Cancer 179:15\u201324. https:\/\/doi.org\/10.1016\/j.ejca.2022.10.029","journal-title":"Eur J Cancer"},{"issue":"11","key":"5751_CR5","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s40264-020-00968-7","volume":"43","author":"E Iwasa","year":"2020","unstructured":"Iwasa E, Fujiyoshi Y, Kubota Y et al (2020) Interstitial lung disease as an adverse drug reaction in Japan: exploration of regulatory actions as a basis for high reporting. Drug Saf 43(11):1121\u20131131. https:\/\/doi.org\/10.1007\/s40264-020-00968-7","journal-title":"Drug Saf"},{"issue":"1","key":"5751_CR6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00408-023-00669-9","volume":"202","author":"N Kanaji","year":"2024","unstructured":"Kanaji N, Ichihara E, Tanaka T et al (2024) Efficacy and safety of re-administration of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) after EGFR-TKI-induced interstitial lung disease (CS-Lung-005). Lung 202(1):63\u201372. https:\/\/doi.org\/10.1007\/s00408-023-00669-9","journal-title":"Lung"},{"issue":"12","key":"5751_CR7","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1164\/rccm.200710-1501OC","volume":"177","author":"S Kudoh","year":"2008","unstructured":"Kudoh S, Kato H, Nishiwaki Y et al (2008) Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 177(12):1348\u20131357. https:\/\/doi.org\/10.1164\/rccm.200710-1501OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"5751_CR8","first-page":"2892","volume":"5","author":"A Midha","year":"2015","unstructured":"Midha A, Dearden S, McCormack R (2015) EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res 5(9):2892\u20132911","journal-title":"Am J Cancer Res"},{"issue":"10","key":"5751_CR9","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10):947\u2013957. https:\/\/doi.org\/10.1056\/NEJMoa0810699","journal-title":"N Engl J Med"},{"key":"5751_CR10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/1756-0500-2-157","volume":"2","author":"M Nakagawa","year":"2009","unstructured":"Nakagawa M, Nishimura T, Teramukai S et al (2009) Interstitial lung disease in gefitinib-treated Japanese patients with non-small cell lung cancer: a retrospective analysis: JMTO LC03-02. BMC Res Notes 2:157. https:\/\/doi.org\/10.1186\/1756-0500-2-157","journal-title":"BMC Res Notes"},{"issue":"4","key":"5751_CR11","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1248\/yakushi.15-00224-5","volume":"136","author":"M Nakamura","year":"2016","unstructured":"Nakamura M (2016) Analysis of spontaneously reported adverse events. Yakugaku Zasshi 136(4):549\u2013556. https:\/\/doi.org\/10.1248\/yakushi.15-00224-5","journal-title":"Yakugaku Zasshi"},{"issue":"4","key":"5751_CR12","doi-asserted-by":"publisher","first-page":"168","DOI":"10.4321\/S1885-642X2006000400004","volume":"4","author":"T Nishimura","year":"2006","unstructured":"Nishimura T, Tada H, Nakagawa M, Teramukai S, Matsui S, Fukushima M (2006) Lessons from gefitinib-induced interstitial lung disease in Japan: problems in approval, pharmacovigilance, and regulatory decision-making procedures. Pharm Pract (Granada) 4(4):168\u2013178. https:\/\/doi.org\/10.4321\/S1885-642X2006000400004","journal-title":"Pharm Pract (Granada)"},{"issue":"3","key":"5751_CR13","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s11523-024-01048-x","volume":"19","author":"N Nishioka","year":"2024","unstructured":"Nishioka N, Imai H, Endo M et al (2024) Real-world data on subsequent therapy for first-line osimertinib-induced pneumonitis: safety of EGFR-TKI rechallenge (Osi-risk study TORG-TG2101). Target Oncol 19(3):423\u2013433. https:\/\/doi.org\/10.1007\/s11523-024-01048-x","journal-title":"Target Oncol"},{"issue":"1","key":"5751_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/jjco\/hyy179","volume":"49","author":"Y Ohe","year":"2019","unstructured":"Ohe Y, Imamura F, Nogami N et al (2019) Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset. Jpn J Clin Oncol 49(1):29\u201336. https:\/\/doi.org\/10.1093\/jjco\/hyy179","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"5751_CR15","doi-asserted-by":"publisher","first-page":"792","DOI":"10.3390\/ijms22020792","volume":"22","author":"T Ohmori","year":"2021","unstructured":"Ohmori T, Yamaoka T, Ando K, Kusumoto S, Kishino Y, Manabe R, Sagara H (2021) Molecular and clinical features of EGFR-TKI-associated lung injury. Int J Mol Sci 22(2):792. https:\/\/doi.org\/10.3390\/ijms22020792","journal-title":"Int J Mol Sci"},{"issue":"Suppl 1","key":"5751_CR16","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.4103\/0976-500X.120955","volume":"4","author":"C Palleria","year":"2013","unstructured":"Palleria C, Leporini C, Chimirri S et al (2013) Limitations and obstacles of the spontaneous adverse drugs reactions reporting: two \u201cchallenging\u201d case reports. J Pharmacol Pharmacother 4(Suppl 1):S66\u2013S72. https:\/\/doi.org\/10.4103\/0976-500X.120955","journal-title":"J Pharmacol Pharmacother"},{"issue":"3","key":"5751_CR17","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"R Rosell","year":"2012","unstructured":"Rosell R, Carcereny E, Gervais R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13(3):239\u2013246. https:\/\/doi.org\/10.1016\/S1470-2045(11)70393-X","journal-title":"Lancet Oncol"},{"key":"5751_CR18","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ejca.2021.09.041","volume":"159","author":"Y Sakata","year":"2021","unstructured":"Sakata Y, Sakata S, Oya Y et al (2021) Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT). Eur J Cancer 159:144\u2013153. https:\/\/doi.org\/10.1016\/j.ejca.2021.09.041","journal-title":"Eur J Cancer"},{"issue":"5","key":"5751_CR19","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/j.chest.2022.05.035","volume":"162","author":"Y Sato","year":"2022","unstructured":"Sato Y, Sumikawa H, Shibaki R et al (2022) Drug-related pneumonitis induced by osimertinib as first-line treatment for epidermal growth factor receptor mutation-positive non-small cell lung cancer: a real-world setting. Chest 162(5):1188\u20131198. https:\/\/doi.org\/10.1016\/j.chest.2022.05.035","journal-title":"Chest"},{"issue":"27","key":"5751_CR20","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","volume":"31","author":"LV Sequist","year":"2013","unstructured":"Sequist LV, Yang JC, Yamamoto N et al (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31(27):3327\u20133334. https:\/\/doi.org\/10.1200\/JCO.2012.44.2806","journal-title":"J Clin Oncol"},{"issue":"20","key":"5751_CR21","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1002\/cam4.4750","volume":"11","author":"R Shibaki","year":"2022","unstructured":"Shibaki R, Ozawa Y, Noguchi S et al (2022) Impact of pre-existing interstitial lung abnormal shadow on lung injury development and severity in patients of non-small cell lung cancer treated with osimertinib. Cancer Med 11(20):3743\u20133750. https:\/\/doi.org\/10.1002\/cam4.4750","journal-title":"Cancer Med"},{"issue":"2","key":"5751_CR22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J et al (2018) Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378(2):113\u2013125. https:\/\/doi.org\/10.1056\/NEJMoa1713137","journal-title":"N Engl J Med"},{"issue":"1","key":"5751_CR23","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.lungcan.2004.01.010","volume":"45","author":"T Takano","year":"2004","unstructured":"Takano T, Ohe Y, Kusumoto M et al (2004) Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer 45(1):93\u2013104. https:\/\/doi.org\/10.1016\/j.lungcan.2004.01.010","journal-title":"Lung Cancer"},{"issue":"1","key":"5751_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3892\/mco.2016.1099","volume":"6","author":"M Takeda","year":"2017","unstructured":"Takeda M, Nakagawa K (2017) Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors in patients with epidermal growth factor receptor gene mutation-positive lung cancer. Mol Clin Oncol 6(1):3\u20136. https:\/\/doi.org\/10.3892\/mco.2016.1099","journal-title":"Mol Clin Oncol"},{"issue":"2","key":"5751_CR25","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/pds.4944","volume":"29","author":"M Tsuchiya","year":"2020","unstructured":"Tsuchiya M, Obara T, Sakai T et al (2020) Quality evaluation of the Japanese Adverse Drug Event Report database (JADER). Pharmacoepidemiol Drug Saf 29(2):173\u2013181. https:\/\/doi.org\/10.1002\/pds.4944","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05751-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05751-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05751-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T03:09:27Z","timestamp":1784862567000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05751-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":25,"alternative-id":["5751"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05751-6","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"12 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JADER data are de-identified and publicly available, institutional review board approval was not required.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable; all materials are original and created by the authors.","order":4,"name":"Ethics","label":"Permission to reproduce material from other sources","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Clinical trial registration","group":{"name":"EthicsHeading","label":"Declarations"}}]}}